CML Therapy Practice: Satellite Symposium

Chronic myelogenous leukemia (CML) is one of the major malignant disorder and accounts for 15%–20% of all cases of leukemia in adults. Despite enormous advancements in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face decision making challenges in the effective treatment of CML patients especially those with prior failed lines of therapy. The TKI therapies has successfully improved the overall survival in CML patients and has transformed CML disease from a fatal to a manageable disease. In recent years, there has been marked increase in the efficacy studies on TKIs usage in resistant CML therapy. These advancements make it difficult for Healthcare professionals (HCPs) to maintain current knowledge in a timely fashion. The overarching goal of this activity is to advance the HCP’s knowledge about latest efficacy updates about TKIs usage in CML management with prior failed lines of therapy, thereby reducing practice gaps by increasing confidence in new therapeutic decision making and ultimately improving the overall patience care.

Proudly supported by

Book My Place

By submitting you agree to the Terms & Privacy Policy

Meet our Speakers

We've gathered some of the top experts in the field to discuss this topic. With years of experience between them, they're well-equipped to offer invaluable insights and perspectives.

Ehab Atallah

Ehab Atallah

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA

Giuseppe Saglio

Giuseppe Saglio

*Division of Internal Medicine and Haematology, University of Turin, Turin, Italy

Kendra Sweet

Kendra Sweet

*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Talks

Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | Satellite Symposium

25 September 2021, 04:00 PM
Kendra Sweet Giuseppe Saglio Ehab Atallah